MoonLake Immunotherapeutics (MLTX) Investors with Substantial Losses Have Opportunity to Lead the MoonLake Class Action Lawsuit -- RGRD LLP

SAN DIEGO, Oct. 15, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that the MoonLake class action lawsuit – captioned Bridgewood v. MoonLake Immunotherapeutics, No. 25-cv-08500 (S.D.N.Y.) – seeks to represent purchasers or acquirers of MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock and charges MoonLake and certain of MoonLake’s top executives with violations of the Securities Exchange Act of 1934. If you suffered substantial losses and wish to serve as lead plaintiff of the Moo ...